

Effects of PeptiSleep on Sleep Quality in Healthy Adults

NCT07258433

Status	RECRUITING
Phase	Not Applicable
Sponsor	Nuritas Ltd
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (13)

- Adults aged 18-65 at the time of enrollment.
 - Generally healthy
 - BMI 18.5 - 35.0kg/m2
 - Willing and able to provide informed consent.
 - Willing to consume one PeptiSleep or placebo capsule daily for 6 weeks.
- ... and 8 more (see full listing online)

Exclusion (21)

- Are currently pregnant, breastfeeding, or planning pregnancy during the study period.
 - Are using prescription or over-the-counter sleep medications (e.g., zolpidem, melatonin >5 mg, benzodiazepines, CBD or antihistamines used for sleep, stress, depression, or anxiety within 4-weeks prior to enrolment.
 - Have a current diagnosis of a chronic medical condition or illness (e.g., uncontrolled thyroid disease, diabetes, cardiovascular disease, major depressive disorder, or anxiety disorder requiring ongoing pharmacologic treatment) or a chronic sleep disorder, insomnia, restless leg syndrome, sleep apnoea.
 - Are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 4-weeks and any other sleep clinical trial during the past 3 months.
 - Have a known allergy or sensitivity to any component of the investigational or placebo product
- ... and 16 more (see full listing online)

Locations (1 total)

Reputable Labs Inc., Wilmington, Delaware, United States

<https://clinicaltrials.gov/study/NCT07258433>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).